Araverus
NewsMarkets
News
HeadlinesThreads
© 2026 Araverus
AboutContactPrivacyTerms
News/Markets/Deals
Top Headline

Boston Scientific Bolsters Cardiovascular Portfolio with $15 Billion Penumbra Thrombectomy Deal

Araverus Team|Thursday, January 15, 2026 at 12:25 PM

Araverus Team

Jan 15, 2026 · 12:25 PM

Boston Scientific · Cardiovascular Treatment · Healthcare M&A · Penumbra Acquisition

Boston ScientificCardiovascular TreatmentHealthcare M&APenumbra Acquisition

Boston Scientific has agreed to acquire Penumbra for over $14 billion, enhancing its cardiovascular treatment portfolio, with shareholders having the option of cash or stock.

Read More On

Boston Scientific to Buy Penumbra for $15 Billion in Cash, Stockwsj.comBoston Scientific to acquire Penumbra in $14.5 billion deal - Investing.cominvesting.comBoston Scientific Agrees to Buy Penumbra in $14.6 Billion Cardiovascular Deal - Yahoo Financefinance.yahoo.comBoston Scientific Buys Penumbra For $14.5 Billion To Expand Vascular Care - Finimizefinimize.comBoston Scientific to Buy Penumbra for $15 Billion in Cash, Stock - morningstar.commorningstar.com

Related Articles

Markets★★Similarity: 64% · 63d ago

TransDigm to Buy Jet Parts Engineering, Victor Sierra Aviation for $2.2 Billion

The two businesses generated about $280 million in combined revenue in 2025.

Tech★★Similarity: 62% · 67d ago

Funding for Risky Biotechs Is Returning

Publicly traded drug developers sold more than $13 billion of shares in the fourth quarter, the most in more than four years.

Markets★★★Similarity: 62% · 59d ago

GSK to Acquire RAPT for $2.2 Billion to Bolster Food Allergy Treatments

The drugmaker said it agreed to pay RAPT Therapeutics shareholders $58 per share, with $1.9 billion upfront investment in cash.

Markets★★★Similarity: 60% · 59d ago

Warner Strikes New All-Cash Deal With Netflix

The media company also released financial details on its soon-to-be spun-off cable networks.